Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors

Cheng William Hong, Lucy Chow, Evrim B. Turkbey, Riccardo Lencioni, Steven K. Libutti, Bradford J. Wood

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: The imaging features of unresectable hepatic malignancies in patients who underwent radiofrequency ablation (RFA) in combination with lyso-thermosensitive liposomal doxorubicin (LTLD) were determined. Materials and Methods: A phase I dose escalation study combining RFA with LTLD was performed with peri- and post- procedural CT and MRI. Imaging features were analyzed and measured in terms of ablative zone size and surrounding penumbra size. The dynamic imaging appearance was described qualitatively immediately following the procedure and at 1-month follow-up. The control group receiving liver RFA without LTLD was compared to the study group in terms of imaging features and post-ablative zone size dynamics at follow-up. Results: Post-treatment scans of hepatic lesions treated with RFA and LTLD have distinctive imaging characteristics when compared to those treated with RFA alone. The addition of LTLD resulted in a regular or smooth enhancing rim on T1W MRI which often correlated with increased attenuation on CT. The LTLD-treated ablation zones were stable or enlarged at follow-up four weeks later in 69 % of study subjects as opposed to conventional RFA where the ablation zone underwent involution compared to imaging acquired immediately after the procedure. Conclusion: The imaging features following RFA with LTLD were different from those after standard RFA and can mimic residual or recurrent tumor. Knowledge of the subtle findings between the two groups can help avoid misinterpretation and proper identification of treatment failure in this setting. Increased size of the LTLD-treated ablation zone after RFA suggests the ongoing drug-induced biological effects.

Original languageEnglish (US)
Pages (from-to)409-416
Number of pages8
JournalCardioVascular and Interventional Radiology
Volume39
Issue number3
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Hot Temperature
Liver
Neoplasms
liposomal doxorubicin
Treatment Failure
Control Groups
Pharmaceutical Preparations

Keywords

  • Hepatocellular carcinoma (HCC)
  • Interventional oncology
  • Radiofrequency ablation
  • Tumor/tumour/neoplasm

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors. / Hong, Cheng William; Chow, Lucy; Turkbey, Evrim B.; Lencioni, Riccardo; Libutti, Steven K.; Wood, Bradford J.

In: CardioVascular and Interventional Radiology, Vol. 39, No. 3, 01.03.2016, p. 409-416.

Research output: Contribution to journalArticle

Hong, Cheng William ; Chow, Lucy ; Turkbey, Evrim B. ; Lencioni, Riccardo ; Libutti, Steven K. ; Wood, Bradford J. / Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors. In: CardioVascular and Interventional Radiology. 2016 ; Vol. 39, No. 3. pp. 409-416.
@article{1423db5afeef48e0aa0dfaa5413ba6ba,
title = "Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors",
abstract = "Introduction: The imaging features of unresectable hepatic malignancies in patients who underwent radiofrequency ablation (RFA) in combination with lyso-thermosensitive liposomal doxorubicin (LTLD) were determined. Materials and Methods: A phase I dose escalation study combining RFA with LTLD was performed with peri- and post- procedural CT and MRI. Imaging features were analyzed and measured in terms of ablative zone size and surrounding penumbra size. The dynamic imaging appearance was described qualitatively immediately following the procedure and at 1-month follow-up. The control group receiving liver RFA without LTLD was compared to the study group in terms of imaging features and post-ablative zone size dynamics at follow-up. Results: Post-treatment scans of hepatic lesions treated with RFA and LTLD have distinctive imaging characteristics when compared to those treated with RFA alone. The addition of LTLD resulted in a regular or smooth enhancing rim on T1W MRI which often correlated with increased attenuation on CT. The LTLD-treated ablation zones were stable or enlarged at follow-up four weeks later in 69 {\%} of study subjects as opposed to conventional RFA where the ablation zone underwent involution compared to imaging acquired immediately after the procedure. Conclusion: The imaging features following RFA with LTLD were different from those after standard RFA and can mimic residual or recurrent tumor. Knowledge of the subtle findings between the two groups can help avoid misinterpretation and proper identification of treatment failure in this setting. Increased size of the LTLD-treated ablation zone after RFA suggests the ongoing drug-induced biological effects.",
keywords = "Hepatocellular carcinoma (HCC), Interventional oncology, Radiofrequency ablation, Tumor/tumour/neoplasm",
author = "Hong, {Cheng William} and Lucy Chow and Turkbey, {Evrim B.} and Riccardo Lencioni and Libutti, {Steven K.} and Wood, {Bradford J.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00270-015-1186-0",
language = "English (US)",
volume = "39",
pages = "409--416",
journal = "CardioVascular and Interventional Radiology",
issn = "7415-5101",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors

AU - Hong, Cheng William

AU - Chow, Lucy

AU - Turkbey, Evrim B.

AU - Lencioni, Riccardo

AU - Libutti, Steven K.

AU - Wood, Bradford J.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Introduction: The imaging features of unresectable hepatic malignancies in patients who underwent radiofrequency ablation (RFA) in combination with lyso-thermosensitive liposomal doxorubicin (LTLD) were determined. Materials and Methods: A phase I dose escalation study combining RFA with LTLD was performed with peri- and post- procedural CT and MRI. Imaging features were analyzed and measured in terms of ablative zone size and surrounding penumbra size. The dynamic imaging appearance was described qualitatively immediately following the procedure and at 1-month follow-up. The control group receiving liver RFA without LTLD was compared to the study group in terms of imaging features and post-ablative zone size dynamics at follow-up. Results: Post-treatment scans of hepatic lesions treated with RFA and LTLD have distinctive imaging characteristics when compared to those treated with RFA alone. The addition of LTLD resulted in a regular or smooth enhancing rim on T1W MRI which often correlated with increased attenuation on CT. The LTLD-treated ablation zones were stable or enlarged at follow-up four weeks later in 69 % of study subjects as opposed to conventional RFA where the ablation zone underwent involution compared to imaging acquired immediately after the procedure. Conclusion: The imaging features following RFA with LTLD were different from those after standard RFA and can mimic residual or recurrent tumor. Knowledge of the subtle findings between the two groups can help avoid misinterpretation and proper identification of treatment failure in this setting. Increased size of the LTLD-treated ablation zone after RFA suggests the ongoing drug-induced biological effects.

AB - Introduction: The imaging features of unresectable hepatic malignancies in patients who underwent radiofrequency ablation (RFA) in combination with lyso-thermosensitive liposomal doxorubicin (LTLD) were determined. Materials and Methods: A phase I dose escalation study combining RFA with LTLD was performed with peri- and post- procedural CT and MRI. Imaging features were analyzed and measured in terms of ablative zone size and surrounding penumbra size. The dynamic imaging appearance was described qualitatively immediately following the procedure and at 1-month follow-up. The control group receiving liver RFA without LTLD was compared to the study group in terms of imaging features and post-ablative zone size dynamics at follow-up. Results: Post-treatment scans of hepatic lesions treated with RFA and LTLD have distinctive imaging characteristics when compared to those treated with RFA alone. The addition of LTLD resulted in a regular or smooth enhancing rim on T1W MRI which often correlated with increased attenuation on CT. The LTLD-treated ablation zones were stable or enlarged at follow-up four weeks later in 69 % of study subjects as opposed to conventional RFA where the ablation zone underwent involution compared to imaging acquired immediately after the procedure. Conclusion: The imaging features following RFA with LTLD were different from those after standard RFA and can mimic residual or recurrent tumor. Knowledge of the subtle findings between the two groups can help avoid misinterpretation and proper identification of treatment failure in this setting. Increased size of the LTLD-treated ablation zone after RFA suggests the ongoing drug-induced biological effects.

KW - Hepatocellular carcinoma (HCC)

KW - Interventional oncology

KW - Radiofrequency ablation

KW - Tumor/tumour/neoplasm

UR - http://www.scopus.com/inward/record.url?scp=84957426386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957426386&partnerID=8YFLogxK

U2 - 10.1007/s00270-015-1186-0

DO - 10.1007/s00270-015-1186-0

M3 - Article

C2 - 26228246

AN - SCOPUS:84957426386

VL - 39

SP - 409

EP - 416

JO - CardioVascular and Interventional Radiology

JF - CardioVascular and Interventional Radiology

SN - 7415-5101

IS - 3

ER -